Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review
ConclusionsDespite high costs, the included studies indicate that imatinib regimens are cost effective in newly diagnosed patients with CP-CML. For people with CML who are resistant or intolerant to standard-dose imatinib, dasatinib is likely to be a more cost-effective strategy in middle-income countries. More studies are necessary to assess the long-term efficacy and cost effectiveness of novel treatment options.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Drugs & Pharmacology | Gleevec | Leukemia | Study